The Safety of Eplerenone in Hemodialysis Patients | Zendy

Michael Walsh | Zendy; Braden Manns | Zendy; Amit X. Garg | Zendy; Joe Bueti | Zendy; Christian G. Rabbat | Zendy; Andrew Smyth | Zendy; Jessica Tyrwhitt | Zendy; Jackie Bosch | Zendy; Peggy Gao | Zendy; P.J. Devereaux | Zendy; Ron Wald | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Safety of Eplerenone in Hemodialysis Patients

Author(s) -

Michael Walsh,

Braden Manns,

Amit X. Garg,

Joe Bueti,

Christian G. Rabbat,

Andrew Smyth,

Jessica Tyrwhitt,

Jackie Bosch,

Peggy Gao,

P.J. Devereaux,

Ron Wald

Publication year - 2015

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.12371214

Subject(s) - eplerenone , medicine , hyperkalemia , discontinuation , placebo , hemodialysis , mineralocorticoid receptor , randomized controlled trial , population , spironolactone , aldosterone , alternative medicine , environmental health , pathology

Mineralocorticoid receptor antagonism reduces morbidity and mortality in patients with heart failure, but the safety of these drugs in patients receiving dialysis is unclear. This study evaluated whether hyperkalemia and/or hypotension limited the use of eplerenone, a selective mineralocorticoid receptor antagonist, in hemodialysis patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research